ARID1A-mutated ovarian cancers depend on HDAC6 activity-Reference-Cited by-同舟云学术

ARID1A-mutated ovarian cancers depend on HDAC6 activity

Published:2017-07-24 Issue:8 Volume:19 Page:962-973
ISSN:1465-7392
Container-title:Nature Cell Biology
language:en
Short-container-title:Nat Cell Biol

Author:

Bitler Benjamin G.,Wu Shuai,Park Pyoung Hwa,Hai Yang^ORCID,Aird Katherine M.,Wang Yemin^ORCID,Zhai Yali,Kossenkov Andrew V.,Vara-Ailor Ana,Rauscher III Frank J.,Zou Weiping,Speicher David W.,Huntsman David G.,Conejo-Garcia Jose R.,Cho Kathleen R.,Christianson David W.,Zhang Rugang^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology

Link

http://www.nature.com/articles/ncb3582.pdf

Reference42 articles.

1. Wilson, B. G. & Roberts, C. W. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11, 481–492 (2011).

2. Kadoch, C. et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 45, 592–601 (2013).

3. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).

4. Jones, S. et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228–231 (2010).

5. Wiegand, K. C. et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363, 1532–1543 (2010).

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression patterns of HDAC6 in correlation to ARID1A status in different subtypes of endometriosis: A retrospective tissue microarray analysis;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-11

2. Chromatin remodellers as therapeutic targets;Nature Reviews Drug Discovery;2024-07-16

3. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair;Gastric Cancer;2024-06-26

4. Working title: Molecular involvement of p53‐MDM2 interactome in gastrointestinal cancers;Cell Biochemistry and Function;2024-06

5. Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis);Cell Death & Disease;2024-05-29